TITLE

PROTHROMBINOPENIC ACTION OF G-23350, A NEW ANTICOAGULANT

AUTHOR(S)
Menéndez, Carlos; Almonte, J. Corral; Ramos, C. Nuñez
PUB. DATE
April 1957
SOURCE
Angiology;Apr1957, Vol. 8 Issue 2, p182
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A new drug of the coumarin group has been used in clinical experiments on 50 hospitalized patients in order to determine its advantages over the other anticoagulants. The hypoprothrombinemic section of G-23350 was uniform and steady (this quality was noticed particularly in the chronic stages) and combined with other substances of rapid action (in the acute stages). As soon as the curves are established at the therapeutic level, this drug can be handled with weekly laboratory determinations. To the patient, this means less money spent in laboratory tests and less trouble. Vitamin K1 is the drug of choice to control any bleeding that may appear and it is not necessary to administer a higher dose than that we used. The recommended initial dose for the G-23350 is 32 mg in a single dose. Maintainance doses may vary from 4 to 8 mg.
ACCESSION #
16351595

 

Related Articles

  • Validity of International Normalized Ratio in Expressing Prothrombin Times in Anticoagulated and Nonanticoagulated Patients. Alshameeri, Rasheed; Mammen, Eberhard F.; Paisley, Christa; Perry, Christine // Clinical & Applied Thrombosis/Hemostasis;Winter1996, Vol. 2 Issue 1, p25 

    We investigated the effect of four thromboplastins with different International Sensitivity Index (ISI) values on prothrombin times (PTs), expressed as International Normalized Ratios (INRs), of 30 normal plasmas, 30 patients on stable oral anticoagulant (OA) therapy, and 30 patients with...

  • CONTROL OF ANTICOAGULANT THERAPY IN HOSPITAL. Hutton, I.; Reid, D.S.; Linton, A.L. // Angiology;May1966, Vol. 17 Issue 5, p292 

    An attempt has been made to assess the degree of control achieved during short term anticoagulant therapy as prescribed by one house physician. Less than 50 per cent of the patients treated proved to be well controlled, and the difficulties encountered are described. It is possible that...

  • Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data? Zalpour, Ali; Kroll, Michael H.; Afshar-Kharghan, Vahid; Yusuf, SyedWamique; Escalante, Carmen // Advances in Hematology;2011, Vol. 2011, p1 

    The association between cancer and venous thromboembolism (VTE) has been well documented in the literature. Prevention and treatment of VTE in cancer patients is imperative. Typically, the mainstay regimen for VTE prevention and treatment has been anticoagulation therapy, unless contraindicated....

  • Anticoagulant (Major drug group).  // Royal Society of Medicine: Medicines;2002, p68 

    The article presents information on anticoagulant agents. These agents prevent the clotting of blood and help break up blood clots that have formed. Therapeutically, anticoagulants are used to prevent the formation of and to treat blood clots in conditions such as thrombosis and embolism,...

  • Independent Nurse: Clinical Top 50 - Oral anticoagulation. Provan, Drew // GP: General Practitioner;12/2/2005, p121 

    This article reports that therapeutic anticoagulation is increasing by 20 percent each year. By 1996, more than 300,000 British patients required oral anticoagulation. It is informed that warfarin is the preferred oral anticoagulant; phenindione is used in cases of warfarin allergy. Oral...

  • The Baylis-Hillman entrée to heterocyclic systems -- the Rhodes contribution. Kaye, Perry T. // South African Journal of Science;Nov/Dec2004, Vol. 100 Issue 11/12, p545 

    This review focuses on applications of the Baylis-Hillman reaction in the synthesis of various heterocyclic products, which include indolizines, chromenes, thiochromenes, coumarins and quinolines. Attention is also given to the mechanistic implications and the elaboration of various products to...

  • FIVE-YEAR STUDY OF ANTICOAGULANTS. Simson, George // Angiology;May1962, Vol. 13 Issue 5, p226 

    Phenprocoumon, a newer anticoagulant, has been evaluated over a five-year period in a 45 patient-years' study. Comparision with Dicumarol is reported, and our experience with the administration and control of the drug is reviewed.

  • PITFALLS IN ANTICOAGULANT THERAPY FOR MYOCARDIAL INFARCTION. Moore, Charles B. // Angiology;Jan1964, Vol. 15 Issue 1, p27 

    The additional evidence to the growing belief that prolonged oral anticoagulant therapy is safe and practical also requires a discussion of the pitfalls in the management of these patients which includes: 1. Difficulties with laboratory determinations and their inability at times to reflect the...

  • Pharmacogenetics of Oral Anticoagulant Therapy. Schalekamp, T.; De Boer, A. // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p187 

    The identification of the genes encoding CYP2C9, the principal metabolizing enzyme of the coumarins, and VKORC1, the molecular target for coumarins, has strongly stimulated the research on pharmacogenetics of vitamin K antagonists, also designated as coumarins. From 1999 to 2004 a number of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics